Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
The International Medical Device Regulators Forum (IMDRF) has published its final technical guidance document, which applies specifically to changes...
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised healthcare organisations and distributors to stop using or supplying six...
The Department of Health and Social Care (DHSC) has published a collection of new and updated guidance on sales, promotion and enforcement...
The European Medicines Agency (EMA) has published guidance on implementing shortage prevention plans (SPPs) for marketing authorisation holders...
This week's edition of Life Sciences weekly highlights includes a key administrative court judgment in R (Bayswater Support Group) v Health Research...
This Practice Note considers the use of specific boilerplate provisions in business-to-consumer (B2C) contracts, namely assignment, definitions and...
This Practice Note sets out the law on the use of boilerplate provisions in business-to-consumer (B2C) contracts. As well as providing details on the...
A–B | C–D | E–H | I–N | O–P.Qualified person (QP)The qualified person (QP) is responsible for ensuring that each batch of medicinal products has been...
Universities and other academic institutions undertake a significant amount of research and therefore generate a lot of protectable IP. The protection...
This Practice Note sets out the UK approach to regulating artificial intelligence (AI) in the UK under its National AI Strategy, including the...
This Agreement is made on [insert date].Parties1[Insert name of first co-owner of patent][ (Company Number [insert number])] [whose [registered office...
This Agreement is made on [insert date]parties1[insert name of manufacturer ][of OR a company incorporated in [England and Wales] under number [insert...
This Agreement is made on [insert date]parties1[insert name of customer ][of OR a company incorporated in [England and Wales] under number [insert...
This Agreement is made on [date]Parties1[Insert the company name] a company registered in [England and Wales] under company number [insert registered...
This Agreement is made on [date]Parties1[insert name of Principal] [of OR a company incorporated in [insert jurisdiction] under number [insert...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
Animal testing refers to the use of live animals in experiments or procedures for scientific, medical, cosmetic, educational or regulatory purposes, often in the context of product safety or biomedical research. In UK law, the practice is primarily regulated by the Animals (Scientific Procedures) Act 1986 (ASPA), which requires a project licence, personal licence and establishment licence, and imposes controls on the care, use, pain relief and euthanasia of “protected animals”. The concept overlaps with statutory terms such as “regulated procedures” under ASPA.
In Ireland, animal testing is governed by legislation implementing Directive 2010/63/EU, with a similar licensing and inspection regime, and parallel concepts such as “procedures” on protected animals. Across England & Wales, Scotland, Northern Ireland and Ireland, animal testing law is underpinned by the Three Rs (replacement, reduction, refinement) and engages administrative, criminal and regulatory law.
The term is significant in advising on compliance, challenging or defending enforcement action, drafting research protocols, procurement and ethics policies, judicial review of licensing decisions, and navigating overlapping regimes on medicines, chemicals, veterinary products and cosmetics.
Making a medicinal product that would normally require authorisation'>marketing authorisation available for compassionate reasons to a group of patients with a chronically or seriously debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorised medicinal product.
Any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for a medical purpose, and which does not achieve its principal intended action by pharmacological, immunological or metabolic means, in or on the human body.